September 2024

Maximizing Success: A Professional, Educated, and Profit-Focused Approach to Blogging AccessWire Article #923254 PHOENIX, AZ / ACCESSWIRE / September 26, 2024 Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT…

Uncovering the Truth: Debunking the Short Report on Super Micro Computer Description I reiterate a ‘Buy’ rating for Super Micro Computer, despite the Hindenburg short report, with a one-year price target of $700 per share. Super Micro’s past accounting violations are acknowledged but resolved; current related-party transactions are fully disclosed and not fundamentally problematic. The…

Welcome to the World of AI Security Towers! An Exciting Expansion Order Wow, did you hear the news? Artificial Intelligence Technology Solutions, Inc. (AITX) just announced a major expansion order for 32 RIO 360 solar-powered security towers! This order comes from an existing client and is a huge win for the company. Talk about impressive…

Welcome to the Nevada Lithium Summit September 29-30, 2024 at Hyatt Regency Lake Tahoe Resort, Incline Village, Nevada RENO, NV / ACCESSWIRE / September 26, 2024 / M2i Global, Inc. (“M2i,” the “Company,” “we,” “our” or “us”) (OTCQB:MTWO), a company specializing in the development and execution of a complete global value supply chain for critical…

Biodexa Pharmaceuticals PLC Interim Results June 30, 2024 Operational Highlights Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announces unaudited interim results for the six months ended June 30, 2024. The Company secured exclusive worldwide licensing of eRapa™, a Phase 3 ready asset targeting Familial Adenomatous Polyposis (“FAP”), along with access to a $17 million…

Unleashing Hope: Longboard Pharmaceuticals Begins Groundbreaking Phase 3 DEEp-SEA Trial for Bexicaserin in Dravet Syndrome Description: LA JOLLA, Calif.–(BUSINESS WIRE)—- $LBPH #Epilepsy–Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational…

Boosting National Preparedness: Emergent BioSolutions Secures $67.4 Million Contract for Additional TEMBEXA (brincidofovir) GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) Eager to protect the nation from potential bioterrorism threats and outbreaks of infectious diseases, Emergent BioSolutions Inc. has recently secured a significant contract aimed at bolstering national preparedness. The $67.4 million contract will provide additional…